Menopause management (1:30), wheezing in children (4:00), prevention of nonsteroidal anti-inflammatory drug–induced ulcers (8:20), infective endocarditis (11:00), acute migraine treatment (17:10), and colchicine for secondary prevention of cardiovascular disease (20:40).
Type 1 diabetes affects approximately 2 million people in the US and 8.4 million people worldwide. Author Desmond Schatz, MD, of the University of Florida joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of type 1 diabetes. Related Content: Type 1 Diabetes
Mark Cuban, entrepreneur, investor, and cofounder of the Mark Cuban Cost Plus Drug Company, joins JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss the role of pharmacy benefit managers, insurance formularies, and opaque pricing practices that shape how most Americans access prescription drugs. Hear why he thinks doctors are the good guys in a broken system. Related Content: Pharmaceutical Pricing—JAMA Talks With Mark Cuban
Opioid use disorder is the third most prevalent substance use disorder worldwide. Author Alexander Walley, MB, MSc, of Boston Medical Center and Boston University joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the efficacy, safety, and practical considerations of treating patients with medications for opioid use disorder, opioid withdrawal, and opioid overdose. Related Content: Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose
This week includes studies on promising new therapies for IgA nephropathy, evolving antithrombotic strategies after coronary stenting, and the inciting antigen in rare vaccine-related clotting syndromes. We review the urgent challenge of mucormycosis and follow the case of a young woman with headaches and hypertension. We discuss human-subjects research. Perspectives examine rural health, data interoperability, drug labels in the courts, and a pediatrician’s dilemma.
In this episode of ECDC On Air, we speak with ECDC's Helena de Carvalho Gomes - Deputy Head of Unit for Scientific Evidence and Communication, and former clinician in obstetrics and gynaecology, about the role of human papillomavirus (HPV) in cervical cancer and how vaccination and screening can prevent the disease. Drawing on her clinical experience, she reflects on changes in cervical cancer prevention over the past 25 years and on the impact of HPV vaccination and screening in reducing pre-cancerous lesions and cancer risk among women.We also discuss why sustained vaccination programmes and…
This week, we look at new evidence on oral cholesterol-lowering therapy, the evolving role of beta-blockers after myocardial infarction, and advances in breast and prostate cancer treatment. We review the inherited risk of coronary disease. We also work through a revealing diagnostic case in a young woman and reflect on science under pressure, corporatized insurance, the reach of FDA law, and what it means to live with life-sustaining technology.
Ovarian cancer may be prevented with removal of the fallopian tubes during pelvic or select abdominal surgery in eligible women. This procedure, opportunistic salpingectomy, can be offered to more eligible women. Author Jurgen M. Piek, MD, PhD, of the Catharina Cancer Institute discusses this and more with JAMA Deputy Editor Linda Brubaker, MD, MS. Related Content: Opportunistic Salpingectomy for Prevention of Tubo-Ovarian Carcinoma
This week, we explore new therapies to reduce pancreatitis risk in severe hypertriglyceridemia, advances in breast cancer treatment, and long-term results of gene therapy for hemophilia B. We discuss vision-threatening vascular emergencies, the mental health effects of firearm injury on families, and care for peripheral artery disease. We also follow a revealing diagnostic case in an older woman with respiratory failure. Perspectives reflect on hypertension control, immunization access, chronic disease policy, and on the inherited risk of disease.
IgA nephropathy is a chronic kidney disease involving deposition of IgA-containing immune complexes in the glomerulus, which often causes kidney failure within 10 to 20 years. Author Michelle Marie O'Shaughnessy, MB, BCh, BAO, MS, of Galway University joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the symptoms, risk factors, diagnosis, treatment, and prognosis of IgA nephropathy in adults. Related Content: IgA Nephropathy in Adults
WHO regrets the United States’ notification of withdrawal from WHO – a decision that makes both the United States and the world less safe. The notification of withdrawal raises issues that will be considered by the WHO Executive Board at its regular meeting starting on 2 February and by the World Health Assembly at its annual meeting in May 2026.